Comparative Pharmacology
Head-to-head clinical analysis: TRI LO LINYAH versus ZOVIA 1 35E 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI LO LINYAH versus ZOVIA 1 35E 21.
TRI-LO-LINYAH vs ZOVIA 1/35E-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin oral contraceptive: suppresses gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, reducing sperm penetration; alters endometrial structure, impairing implantation.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibits ovulation, alters cervical mucus and endometrial lining.
One tablet orally once daily for 21 days, followed by 7 days of placebo. Each tablet contains 0.180 mg norgestimate and 0.025 mg ethinyl estradiol for days 1-7, 0.215 mg/0.025 mg for days 8-14, and 0.250 mg/0.025 mg for days 15-21.
One tablet orally once daily at the same time each day for 21 days, followed by 7 placebo tablets (if included in the pack) or a 7-day pill-free interval. Each tablet contains ethinyl estradiol 0.035 mg and norethindrone 1 mg.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; allows once-daily dosing but requires dose adjustment in renal impairment.
Norethindrone: 5-12 hours (terminal elimination half-life, approximately 8 hours). Ethinyl estradiol: biphasic with terminal half-life of 10-20 hours (mean 15 hours). Clinical context: Steady state reached in 5-7 days.
Renal: ~60% as unchanged drug; fecal/biliary: ~40% as metabolites.
Renal (approximately 40% as parent drug and metabolites; 20-40% as metabolites; 15-20% as unchanged drug), fecal (30-50% via bile as metabolites), and less than 2% in breast milk.
Category C
Category C
Oral Contraceptive
Oral Contraceptive